Biopôle-based Atinary Technologies joins forces with Takeda, Japan's largest pharmaceutical company, to boost innovation in the healthcare sector. To accelerate R&D and the discovery of revolutionary molecules and materials, Atinary has developed a machine-learning-based platform that outperforms traditional trial-and-error methods.
In a milestone achievement, Atinary Technologies has announced a strategic collaboration with Takeda, the largest Japanese pharmaceutical company. Through this collaboration, Takeda will leverage Atinary's leading AI Self-Driving Labs (SDLabs) technology, that combined with its expertise in R&D and drug discovery aim to create a more robust and efficient drug development process, ultimately benefiting patients worldwide.
Speaking of this collaboration, Atinary co-founder Loïc Roch says: “At Atinary, we are committed to harnessing the power of AI, data science, robotics, and cloud computing to dramatically accelerate the discovery and development of breakthrough molecules. Our collaboration with Takeda Pharmaceuticals is a significant step towards achieving this goal. We look forward to working together to revolutionize the field of drug development and improve healthcare outcomes.”
Supported by the Biopôle Lausanne, the Swiss Healthcare IT startup founded by Hermann Tribukait and Loic Roch, secured in September 2023 a seed round of USD 5 million to enable the startup to scale, grow the team and advance the platform. This strategic alliance with Takeda is an example of how technology and healthcare can come together to create innovative solutions to the pressing challenges of drug development.
(PR - ES)
Photo: Hermann Tribukait and Loïc Roch
Please login or sign up to comment.
Commenting guidelines